Abstract

FORMULATION AND EVALUATION OF MUCOADHESIVE ORAL DISINTEGRATING TABLETS OF BEZAFIBRATE FOR ATHEROSCLEROSIS: TARGETING LIPOPROTEIN LIPASE ACTIVATION AND ANTICOAGULATION

Abhishek Pawar*, Prof. Ashwini Wakade and Dr. Megha Salve

Abstract

In order to improve therapeutic outcomes in atherosclerosis by increasing lipoprotein lipase (LPL) activation and exerting anticoagulant effects, the current study focuses on the formulation and evaluation of mucoadhesive oral disintegrating tablets (ODTs) containing bezafibrate. A derivative of fibric acid called bezafibrate is essential for regulating lipid profiles and encouraging fibrinolysis. In order to improve therapeutic outcomes in atherosclerosis by increasing lipoprotein lipase (LPL) activation and exerting anticoagulant effects, the current study focuses on the formulation and evaluation of mucoadhesive oral disintegrating tablets (ODTs) containing bezafibrate. A derivative of fibric acid called bezafibrate is essential for regulating lipid profiles and encouraging fibrinolysis. Its delayed beginning of action and poor absorption, however, limit its traditional oral delivery. Using direct compression techniques and polymers including carbopol 934P, hydroxypropyl methylcellulose (HPMC K4M), and sodium starch glycolate, mucoadhesive ODTs were created to address these issues by improving mucosal retention, encouraging quick breakdown, and guaranteeing sustained release. Precompression parameters (angle of repose, bulk, and tapped density) and post-compression properties (disintegration time, mucoadhesive strength, friability, hardness, and uniformity of drug content) were assessed for the tablets. Drug release kinetics and mucosal retention were evaluated by ex vivo mucoadhesion and in vitro dissolution investigations. In accordance with the intended pharmacokinetic goals, the improved formulation showed sustained drug release for eight hours, prolonged mucosal adherence for more than four hours, and fast disintegration within 30 seconds. Bezafibrate mucoadhesive ODTs offer a useful platform for enhancing bioavailability, promoting quick onset, and guaranteeing sustained therapeutic action.

Keywords: Bezafibrate, Mucoadhesive tablets, Oral disintegrating tablets (ODTs), Atherosclerosis, Anticoagulation, Cardiovascular therapeutics.